Gastroenterology Consultants of SW Virginia
Raonoke, Virginia, 24014, United States
Location status: Recruiting
Location contact
Vishal Bhagat
CONTACT
NCT Number: NCT06059963
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
Interested in participating?
Request Info45 year–84 year
All sexes
Observational
Raonoke, Virginia, 24014, United States
Location status: Recruiting
Vishal Bhagat
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
Time frame: 1 year
The primary objective of this study is to determine the sensitivity for CRC and specificity for advanced neoplasia (AN). Advance Neoplasia (AN) is defined as a final diagnosis of CRC or Advanced Precancerous Lesion (APL).
Time frame: 1 year
To determine sensitivity for advanced precancerous lesions (APL). To determine NPV and PPV for colorectal cancer.
Contact information is provided by the study sponsor or research team.
Universal Diagnostics
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04739722
Advanced Adenocarcinoma, Colonic Diseases
St Louis, Missouri, United States
View Trial DetailsNCT04722055
Advanced Adenocarcinoma, Colonic Diseases
Jinan, Shandong, China
View Trial DetailsNCT05374369
Advanced Adenocarcinoma, Colonic Diseases
Dongguan, Guangdong, China
View Trial DetailsNCT07736495
Colonic Diseases, Colorectal Cancer
Cairo, Egypt
View Trial Details